Hormone implant aimed at saving uteruses after failed ablation – trial pulled

NCT ID NCT05227456

Terminated Disease control Sponsor: Saskatchewan Health Authority - Regina Area Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study planned to test whether an etonogestrel implant (Nexplanon) could reduce the need for hysterectomy in women who still had abnormal bleeding or pelvic pain after endometrial ablation. The trial was withdrawn before enrolling any participants, so no data were collected. The implant releases a hormone to control bleeding and pain, but its effectiveness in this specific situation remains unknown.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: etonogestrel implant (Nexplanon)
What this could lead to: If it had worked, this could have offered a way to avoid hysterectomy for women with continued bleeding or pain after endometrial ablation.
What could go wrong: The trial was withdrawn before enrolling any participants, so no results are available. Etonogestrel implants can cause side effects like irregular bleeding, mood changes, or weight gain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABNORMAL UTERINE BLEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dysmenorrhea Metrorrhagia Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABNORMAL UTERINE BLEEDING DYSMENORRHEA

Contacts and locations

Locations

Saskatchewan Health Authority

Regina, Saskatchewan, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.